Infections Requiring Infectious Disease Consultation in Hospital Settings
Infectious disease (ID) consultation is essential for complex infections, immunocompromised patients, and multidrug-resistant organisms to reduce morbidity and mortality.
Critical Infections Requiring Mandatory ID Consultation
Bloodstream Infections
- Bacteremia with multidrug-resistant organisms
- Persistent bacteremia despite appropriate therapy
- Fungemia/candidemia 1
- Complicated Staphylococcus aureus bacteremia
- Gram-positive cocci in clusters with systemic symptoms 1
Infections in Immunocompromised Hosts
- Infections in cancer patients receiving chemotherapy 1
- Infections in HIV patients with low CD4 counts
- Febrile neutropenia in the context of appropriate prophylaxis 1
- Infections in solid organ or bone marrow transplant recipients 1
- Infections in patients on biological immunomodulators
Difficult-to-Treat Infections
- Endocarditis
- Osteomyelitis
- Prosthetic joint infections
- Vascular graft infections
- Central nervous system infections (meningitis, encephalitis, brain abscess)
- Complicated intra-abdominal infections
Multidrug-Resistant Organism (MDRO) Infections
- Methicillin-resistant Staphylococcus aureus (MRSA) with complex presentations
- Vancomycin-resistant Enterococcus (VRE)
- Extended-spectrum beta-lactamase (ESBL) producing organisms
- Carbapenem-resistant Enterobacteriaceae (CRE)
- Multidrug-resistant tuberculosis
Specific Clinical Scenarios Requiring ID Consultation
Respiratory Infections
- Complicated pneumonia not responding to initial therapy
- Suspected or confirmed tuberculosis
- Pneumocystis jirovecii pneumonia
- Invasive pulmonary aspergillosis
Gastrointestinal Infections
- Recurrent or severe Clostridioides difficile infections
- Complicated hepatitis B or C infections 1
- Parasitic infections
Skin and Soft Tissue Infections
- Necrotizing fasciitis
- Severe cellulitis in immunocompromised patients 1
- Cellulitis with intravascular or valvular prosthesis 1
- Cellulitis with high risk of non-standard pathogens 1
Viral Infections
- Cytomegalovirus (CMV) infections 1
- Complicated herpes infections
- Severe COVID-19 with secondary infections
When to Consult Based on Patient Characteristics
Immunocompromised States
- Patients with malignancy on chemotherapy 1
- Neutropenic patients 1
- Severe cell-mediated immunodeficiency 1
- HIV patients with opportunistic infections 1
- Transplant recipients (solid organ or bone marrow) 1
Special Exposure Situations
Treatment Challenges
- Patients with multiple drug allergies, especially penicillin allergy
- Patients requiring prolonged antimicrobial therapy
- Patients with renal or hepatic impairment requiring complex dosing adjustments 2
- Patients failing standard antimicrobial therapy
Diagnostic Dilemmas Requiring ID Consultation
- Fever of unknown origin
- Unexplained sepsis
- Culture-negative endocarditis
- Recurrent infections despite appropriate therapy
- Unusual or rare pathogens
Infection Prevention and Control Situations
- Outbreak investigations
- Hospital-acquired infections in high-risk units 3
- Infections with highly transmissible pathogens
- Implementation of isolation precautions for unusual organisms
Practical Considerations
- Early ID consultation (within 48-72 hours) for complex infections improves outcomes
- Consultation is particularly valuable for clinicians unfamiliar with complex antibiotic therapy 1
- A multidisciplinary team approach including ID specialists has been shown to decrease amputation rates and improve outcomes 1
- For hospitals without on-site ID specialists, consider telemedicine consultation 1
Common Pitfalls to Avoid
- Delaying ID consultation for persistent or worsening infections
- Failing to consult ID for immunocompromised patients with fever
- Not obtaining ID input for multidrug-resistant organism infections
- Managing complex infections requiring prolonged antimicrobial therapy without ID expertise
- Treating unusual or rare pathogens without specialist guidance
Remember that early ID consultation can significantly improve patient outcomes by ensuring appropriate antimicrobial selection, optimizing dosing, minimizing adverse effects, and reducing unnecessary antibiotic use.